This review (2026) summarises the rapidly growing evidence for psychedelic-assisted therapies, finding the strongest support for psilocybin in treatment-resistant depression (TRD) and MDMA in post-traumatic stress disorder (PTSD). It also highlights that while these treatments are generally well tolerated in controlled settings, major challenges remain around unclear mechanisms, trial limitations, scalability, and translation into routine practice.
- Published
- Journal
- BMJ
- Authors
- Jacobs, E., Zahid, Z., Hinkle, J., Nayak, S., Yaden, D. B.